Fluvoxamine

(Brand Name: Faverin, Luvox)

Fluvoxamine was the first SSRI approved for clinical use here in the United Kingdom, and was developed by Kali-Duphar in Belgium and introduced as Floxyfral in Switzerland and Solvay in West Germany in 1983. It was approved by the FDA on 5 Dec, 1994 and introduced as Luvox in the US.

Key Facts:
  • NICE report that Fluvoxamine can affect an unborn baby, so it is important to tell your doctor straight away if you’re trying to get pregnant or become pregnant while taking it
  • Fluvoxamine can cause withdrawal symptoms so don’t stop taking it without talking to your doctor
  • In the United States, Fluvoxamine carries a warning stating it may increase suicidal thinking and behaviour in those under age 24

Medication Information

Skeletal formula of fluvoxamine

Skeletal formula of fluvoxamine

The following information is a guide only, a doctor may want to try dosages outside these recommended guides.

When: In the evening before bedtime.

Child dose: Consult a doctor.

Adult dose: The usual initial dose for adults is 50mg daily and is increased gradually if necessary up to a maximum of 300 mg daily.

Older people: Consult a doctor.

Half-Life:  Around 12–13 hours for a single dose, increasing up to  22 hours for regular use.

Pregnancy and Breast Feeding: Fluvoxamine is generally not recommended in pregnancy or while breastfeeding. A doctor will want to prescribe Fluvoxamine only when the benefits of you taking the medicine outweigh the risks. Fluvoxamine and similar antidepressants have been linked with a small risk of problems for the unborn baby when taken in early or late pregnancy. Fluvoxamine passes into breast milk and has been linked with side effects, including withdrawal symptoms, in breastfed babies.

The NICE guidelines, published in 2005, reported that Fluvoxamine has a UK marketing authorisation for treating OCD in children aged 8 years and older.

What to read next: